In Vitro Bioequivalence for Pulmonary and Nasal Delivery

ONdrugDelivery Issue No 102, November 11th, 2019
PULMONARY & NASAL DELIVERY

With a focus on bioequivalence testing in the development of generic inhalables, Mark Parry, Technical Director, Intertek Melbourn, highlights some of the shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques that Intertek offers to allow its clients to de-risk clinical studies or even to support robustly in vitro data submissions as to avoid clinical work.

Please complete the form to download the article.